_256_384.jpg)
News | March 01, 2024
Suven announces merger of Cohance Lifesciences
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
The inspection concluded with no observation (FDA-483) issued.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)